Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2023-08-24 Governance Information
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Appendix 4G 12 pages 260.9KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and references the ASX Corporate Governance Council Principles and Recommendations. It includes a key to disclosures related to corporate governance and mentions compliance with Listing Rules 4.10.3 and 4.7.4. The document is a form used to confirm that the entity has met disclosure requirements regarding corporate governance statements, which are either included in the annual report or available on the company's website. It is not the corporate governance statement itself but a verification and key to locating governance disclosures. This type of document aligns with Governance Information filings, which detail the company's internal rules, board structure, and governance practices. The document length (15,000 characters) and content confirm it is a substantive governance disclosure rather than a brief announcement or a different filing type.
2023-08-24 English
Application for quotation of securities - ANP 6 pages 27.6KB
Capital/Financing Update Classification · 100% confidence The document is an application for quotation of securities on the ASX by Antisense Therapeutics Limited. It details the number and type of securities to be quoted, issue dates, and references a previously announced Appendix 3B (which is a form related to new securities issuance). The document is focused on the listing and quotation of new shares following a capital raising event. It is not a financial report, earnings release, or management discussion. It is an announcement related to capital structure changes and securities issuance. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and content confirm it is not a mere announcement of a report but a substantive filing about securities quotation.
2023-08-21 English
Change of Director's Interest Notice (CG,JG) 4 pages 303.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including number of shares/options held before and after the change, nature of the change, and dates. This type of document is a formal notification of personal share transactions by company directors. It does not contain financial performance data, earnings, or management discussion. It is not an announcement of a report but a direct report of insider transactions. Therefore, it fits the category of Director's Dealing (DIRS). The document length and detail support a high confidence classification.
2023-08-21 English
Antisense Share Purchase Plan (SPP) Raises $3.26 Million 1
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 21 August 2023 regarding the completion of a Share Purchase Plan (SPP) by Antisense Therapeutics Limited. It details the amount raised ($3.26 million), the purpose of the funds, and the listing of shares issued under the SPP. There is no financial report or detailed financial statements included, only an update on a capital raising event. This fits the definition of a Capital/Financing Update (CAP), which covers company fundraising and capital structure changes. The document length is short and focused solely on the financing announcement, not a full report or regulatory filing.
2023-08-20 English
Commencement of Chief Executive Officer 1 page 93.9
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 7 August 2023 regarding the commencement of a new Chief Executive Officer and Managing Director at Antisense Therapeutics Limited. It details the appointment of Dr James Garner, his background, and the leadership transition within the company. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no audit information, and no report attachments. The content is focused on management changes at the board/executive level. The document length is short (2665 characters), and it is clearly an announcement of a management change rather than a report or presentation. Therefore, the appropriate classification is Board/Management Information (MANG).
2023-08-06 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 856.9KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement dated 28 July 2023 providing a quarterly activities report and Appendix 4C for the period ended 30 June 2023. It includes detailed operational updates, clinical trial progress, capital raising information, management appointment, and a detailed Appendix 4C cash flow report. Appendix 4C is a standard quarterly cash flow report required by the ASX Listing Rules. The document contains substantive financial data and analysis for the quarter, not just an announcement or link to a report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2023
2023-07-27 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.